Pfizer Corporation

Truebinding, Inc.

Ksenya Shchors

James Reasoner Apgar

Tao He

Jeffrey Raymond Chabot

Matthew Allister Lambert

Kevin Charles Beaumont

Danna M Breen

Yan Wang

Dongxu Sun

Catherine A Gordon

Tsung-Huang Tsai

Yew Ann Leong

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.

Methods of treating inflammatory diseases by blocking Galectin-3

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.

Anti-GDF15 antibodies, compositions and methods of use

Growing community of inventors

San Mateo, CA, United States of America

Ksenya Shchors